| 13.34 1.03 (8.37%) | 11-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 16.28 |
1-year : | 19.01 |
| Resists | First : | 13.93 |
Second : | 16.28 |
| Pivot price | 12.84 |
|||
| Supports | First : | 12.74 |
Second : | 12 |
| MAs | MA(5) : | 12.65 |
MA(20) : | 12.79 |
| MA(100) : | 14.42  |
MA(250) : | 15.05 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 33.6 |
D(3) : | 24.9 |
| RSI | RSI(14): 53.5 |
|||
| 52-week | High : | 19.6 | Low : | 12 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NPCE ] has closed below upper band by 16.9%. Bollinger Bands are 29.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.95 - 14.02 | 14.02 - 14.08 |
| Low: | 12.64 - 12.71 | 12.71 - 12.77 |
| Close: | 13.23 - 13.34 | 13.34 - 13.44 |
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Wed, 04 Nov 2026
NeuroPace Must Show Core RNS Strength Can Carry The Story While IGE Approval Stalls - Finviz
Sun, 18 Oct 2026
NeuroPace, Inc. (NPCE) - What Are Brokerages Saying About This Stock? - MarketBeat
Thu, 15 Oct 2026
NeuroPace (NPCE) Slips to $12.56 as Shares Consolidate Below Resistance - Island Reversal - https://www.dars.gov.et/
Thu, 10 Sep 2026
Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report? - Yahoo Finance
Tue, 01 Sep 2026
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference - Business Wire
Tue, 18 Aug 2026
NeuroPace Inc (NPCE) (Q2 2026) Earnings Call Highlights: Strong RNS Growth and AI Launch Offset ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 34 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 4.4 (%) |
| Held by Institutions | 97.3 (%) |
| Shares Short | 904 (K) |
| Shares Short P.Month | 911 (K) |
| EPS | -0.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | -17.9 % |
| Operating Margin | -22.6 % |
| Return on Assets (ttm) | -7.5 % |
| Return on Equity (ttm) | -103.3 % |
| Qtrly Rev. Growth | 17.1 % |
| Gross Profit (p.s.) | 2.41 |
| Sales Per Share | 3.11 |
| EBITDA (p.s.) | -0.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -23.41 |
| PEG Ratio | 0 |
| Price to Book value | 38.11 |
| Price to Sales | 4.27 |
| Price to Cash Flow | -40.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|